· Published by Health Canada · Official notice
This is duplicated text of a letter from Baxter Corporation.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
August 15, 2011
Subject: Association of mesna (Uromitexan), multi-dose vials with fatal gasping syndrome in children
This letter is being sent out following consultation with Health Canada regarding mesna (Uromitexan) multi-dose vials which was recently approved in Canada. Baxter Corporation is issuing this letter to ensure that prescribers have the most recent information available when considering mesna (Uromitexan) as a treatment option in the prevention of blood in urine.
Mesna (Uromitexan), multi-dose vials is indicated for the reduction and prevention of bleeding from the bladder caused by the treatment with a group of drugs called oxazaphosphorines (such as Ifosfamide, Glufosfamide and Cyclophosphamide).
To read the full content of the Dear Health Professional Letter (DHPL) for Mesna (UROMITEXAN), Multi-Dose Vials - Association with Fatal Gasping Syndrome in Neonates and Infants - For Health Professionals.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of fatal or life-threatening respiratory syndrome or other serious or unexpected adverse reactions in patients receiving UROMITEXAN should be reported to Baxter Corporation or Health Canada.
Baxter Corporation,
Mississauga, Ontario
1-888-719-9955
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction and Medical Device Problem Reporting section.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Adel Gehchan, MD
Director, Medical and Clinical Affairs
Baxter Corporation